Trial Profile
Analysis of efficacy and safety of tacrolimus extended-release formulation on prevention of rejection and GVHD in allo-HSCT patients
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 May 2012
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 24 May 2012 New trial record